Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Non-Current Deffered Revenue (2022 - 2024)

Atara Biotherapeutics' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $470000.0 for Q3 2024.

  • For Q3 2024, Non-Current Deffered Revenue fell 99.36% year-over-year to $470000.0; the TTM value through Sep 2024 reached $470000.0, down 99.36%, while the annual FY2023 figure was $37.6 million, 51.22% down from the prior year.
  • Non-Current Deffered Revenue reached $470000.0 in Q3 2024 per ATRA's latest filing, down from $567000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $78.0 million in Q1 2023 to a low of $470000.0 in Q3 2024.
  • Average Non-Current Deffered Revenue over 3 years is $43.1 million, with a median of $43.3 million recorded in 2022.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 74.62% in 2023, then tumbled 99.36% in 2024.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $77.0 million in 2022, then tumbled by 51.22% to $37.6 million in 2023, then tumbled by 98.75% to $470000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATRA's Non-Current Deffered Revenue are $470000.0 (Q3 2024), $567000.0 (Q2 2024), and $719000.0 (Q1 2024).